RxTrials Institute Drug Pipeline Alert

TAP Pharmaceutical Products saw favorable results from three Phase III studies evaluating its investigational new drug TAK-390MR, a proton pump inhibitor with dual-delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE.

Data from the two EE healing studies demonstrated that patients treated with the drug at 60 mg and 90 mg experienced higher overall healing after eight weeks compared with patients taking lansoprazole at 30 mg.

In addition, data from a six-month maintenance study showed that patients treated with the drug at 30 mg and 60 mg experienced overall maintenance and symptom relief over placebo, according to TAP.